ACELRX PHARMACEUT. DL-01 Total Liabilities
ACELRX PHARMACEUT. DL-01 total liabilities. Based on the latest financial reports, ACELRX PHARMACEUT. DL-01 (R5XA) has total liabilities worth €12.68 Million EUR (≈ $14.83 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are ACELRX PHARMACEUT. DL-01's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ACELRX PHARMACEUT. DL-01 (2021–2025)
Total liabilities of ACELRX PHARMACEUT. DL-01 from 2021 to 2025. This chart illustrates how ACELRX PHARMACEUT. DL-01's total liabilities have evolved over time, based on quarterly financial data.
ACELRX PHARMACEUT. DL-01 Competitors by Total Liabilities
The table below lists competitors of ACELRX PHARMACEUT. DL-01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dividend Select 15 Corp
TO:DS
|
Canada | CA$503.98K |
|
Corline Biomedical AB
ST:CLBIO
|
Sweden | Skr15.18 Million |
|
Eightco Holdings Inc.
NASDAQ:OCTO
|
USA | $40.18 Million |
|
HLV LIMITED
NSE:HLVLTD
|
India | Rs1.71 Billion |
|
Suratwwala Business Group Limited
NSE:SBGLP
|
India | Rs1.27 Billion |
|
Rubicon Water Ltd
AU:RWL
|
Australia | AU$41.06 Million |
|
KRONA PUBLIC REAL ESTATE
F:927
|
Germany | €911.60 Million |
|
Indopoly Swakarsa Industry Tbk
JK:IPOL
|
Indonesia | Rp198.53 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ACELRX PHARMACEUT. DL-01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ACELRX PHARMACEUT. DL-01 asset portfolio.
Liquidity & Leverage Metrics
ACELRX PHARMACEUT. DL-01 Total Liabilities Ratios Explained
ACELRX PHARMACEUT. DL-01 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACELRX PHARMACEUT. DL-01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the annual total liabilities of ACELRX PHARMACEUT. DL-01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €12.68 Million ≈ $14.83 Million |
+23.93% |
| 2024-12-31 | €10.23 Million ≈ $11.97 Million |
+62.72% |
| 2023-12-31 | €6.29 Million ≈ $7.35 Million |
-75.50% |
| 2022-12-31 | €25.67 Million ≈ $30.01 Million |
-77.44% |
| 2021-12-31 | €113.79 Million ≈ $133.03 Million |
-- |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more